Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial
{"Image DocumentName": "Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial", "Image ImageDescription": "H.A.M.Kerstjens J Allergy Clin Immunol 2011;128: FIG 2. FEV1 (A) and FVC (B) responses relative to baseline values within 3 hours after dosing after 8 weeks of. treatment. The difference in level at 0:00 h is the trough effect of tiotropium administered 24 hours earlier. The measurement obtained at baseline (visit 2 before any maintenance or study medication) is defined as. the baseline value. At the on-treatment visits, this was immediately followed by the usual medication. (including ICS plus LABA), and this in turn was followed by the study medication. Error bars represent. SEMs. Arrows indicate the timing of the maintenance medication: ICS plus LABA. Tiotropium R5, 5 mg of. tiotropium; Tiotropium R10, 10 mg of tiotropium. FIG 3. Twenty-four-hour FEV1 (A) and FVC (B) responses as shown in Fig 2 in the subgroup of patients with. 24-hour assessments (n 5 67). The baseline value was defined on visit 2 before any maintenance or study. medication. At the on-treatment visits, this was immediately followed by the usual medication (including. ICS plus LABA), which was followed in turn by the study medication. The afternoon dosing of ICS plus. LABA treatment was also taken. Error bars represent SEMs. Arrows indicate the timing of the maintenance. medication: ICS plus LABA. Tio R5, 5 mg of tiotropium; Tio R10, 10 mg of tiotropium.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}